Limited efficacy of intratumoral IL-2 applied to large melanoma metastases
详细信息 查看全文
- 作者：Benjamin Weide (1)
Thomas Kurt Eigentler (1)
Giuliano Elia (2)
Dario Neri (3)
Claus Garbe (1) - 刊名：Cancer Immunology, Immunotherapy
- 出版年：2014
- 出版时间：November 2014
- 年：2014
- 卷：63
- 期：11
- 页码：1231-1232
- 全文大小：147 KB
- 参考文献：1. Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pfohler C, Garbe C (2011) Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 60(4):487鈥?93. doi:10.1007/s00262-010-0957-3 CrossRef
2. Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C (2014) Intralesional treatment of Stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunological responses. Cancer Immunol Res. doi:10.1158/2326-6066.cir-13-0206
3. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17):4139鈥?146. doi:10.1002/cncr.25156 CrossRef
4. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620鈥?626. doi:10.1038/sj.bjc.6601320 CrossRef
5. Antony PA, Restifo NP (2005) CD4+ CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28(2):120鈥?28 CrossRef
6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105鈥?116
7. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3):751鈥?58. doi:10.1038/jid.2012.376 CrossRef - 作者单位：Benjamin Weide (1)
Thomas Kurt Eigentler (1)
Giuliano Elia (2)
Dario Neri (3)
Claus Garbe (1)
1. Department of Dermatology, University Medical Center, Liebermeisterstrasse 25, 72076, T眉bingen, Germany
2. Philochem AG, Otelfingen, Switzerland
3. ETH Zurich, Zurich, Switzerland - ISSN：1432-0851
文摘